Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 9;25(1):57.
doi: 10.1007/s11910-025-01446-2.

Psychedelics and Headache Disorders: an Update

James J H Im  1   2 , Claire H Sandoe  3   4
Affiliations
Review

Psychedelics and Headache Disorders: an Update

James J H Im et al. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: Psychedelics are often queried as a potential therapeutic option in a multitude of conditions, including pain and mental health disorders, with a growing body of patient reports and scientific publications describing potential benefit. This article reviews recent research on psychedelic compounds for treatment of headache disorders.

Recent findings: Observational data, case reports, and a few recent small, controlled trials suggest symptom benefit at sub-hallucinogenic doses for both migraine and cluster headache. There have not been new completed studies of psychedelics in other headache disorders. Safety signals also tend to be favorable, although there are continuing concerns for systemic and psychiatric effects in varying doses, preparations and clinical contexts. While available studies on psychedelics suggest potential benefit in cluster headache and migraine, access remains complex due to legal considerations, and additional studies are needed to confirm their effectiveness and to ensure safety before they can be recommended for use.

Keywords: Cluster headache; DMT; Headache; LSD; Migraine; Psilocybin; Psychedelics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

References

    1. Goel A, Rai Y, Sivadas S, Diep C, Clarke H, Shanthanna H, et al. Use of psychedelics for pain: A scoping review. Anesthesiology. 2023;139(4):523–36. - PubMed
    1. Schindler EAD. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology. 2022;215:109166. - PubMed
    1. Schindler EAD. Psychotropic drugs reemerging as headache medicines. CNS Drugs. 2024;38(9):661–70. - PubMed
    1. Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383–94. - PubMed
    1. Schindler EAD, Hendricks PS. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Rev Neurother. 2023;23(10):867–82. - PubMed

MeSH terms

LinkOut - more resources